Human papilomavírus vaccination and screening for anal lesions

Authors

DOI:

https://doi.org/10.5327/2237-4574-238

Abstract

***

References

Karita HCS, Magaret AS, Doody DR, Schouten JT, Mao C, Huh WK, et al. Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): a randomized, double-blind, placebo-controlled trial. Int J Cancer. 2026;158(11):2983-94. https://doi.org/10.1002/ijc.70366

Wilkin TJ, Chen H, Cespedes MS, Leon-Cruz JT, Godfrey C, Chiao EY, et al. A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018;67(9):1339-46. https://doi.org/10.1093/cid/ciy274

Bennis SL, Yared NF, Horvath KJ, Baker JV, Waterboer T, Thyagarajan B, et al. HPV vaccination status in HIV-negative MSM and its association with high-risk HPV detection using HPV serology and anorectal swabs. Vaccines (Basel). 2024;12(10):1154. https://doi.org/10.3390/vaccines12101154

Albuquerque A, Fontes F. Recent guidelines on anal cancer screening: a systematic review. J Low Genit Tract Dis. 2025;29(2):180-5. https://doi.org/10.1097/lgt.0000000000000878

Published

2026-08-11

How to Cite

1.
Guimarães ICC do V, Borba MR, de Carvalho NS, Alves RRF, Nadal SR, Manzione TS, et al. Human papilomavírus vaccination and screening for anal lesions. Rev Bras Patol Trato Genit Inferior [Internet]. 2026 Aug. 11 [cited 2026 Aug. 29];10(01). Available from: https://rbptgi.emnuvens.com.br/revista/article/view/238

Issue

Section

Technical Recommendations